Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan CD44-activated head and neck squamous cell carcinoma cells
MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyal...
Saved in:
Published in | Oncogene Vol. 31; no. 2; pp. 149 - 160 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
12.01.2012
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog–Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog–Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog–Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. |
---|---|
AbstractList | MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog–Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog–Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog–Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. MicroRNAs are often associated with the pathogenesis of many cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to play a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation (ChIP) assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs (siRNAs) effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression, but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 plays a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog--Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/ Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi: 10.1038/onc.2011.222; published online 20 June 2011 Keywords: nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog--Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/ Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. |
Audience | Academic |
Author | Krueger, K Spevak, C C Bourguignon, L Y W Earle, C Wong, G |
Author_xml | – sequence: 1 givenname: L Y W surname: Bourguignon fullname: Bourguignon, L Y W email: lilly.bourguignon@ucsf.edu organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2) – sequence: 2 givenname: C surname: Earle fullname: Earle, C organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2) – sequence: 3 givenname: G surname: Wong fullname: Wong, G organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2) – sequence: 4 givenname: C C surname: Spevak fullname: Spevak, C C organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2) – sequence: 5 givenname: K surname: Krueger fullname: Krueger, K organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21685938$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ksluFDEQhlsoiCxw44wsOBAkevDSmy9Io2GVQpAInK2KXT3jpNue2N0ReSTeEvdMSAgC5INl-6vftfz72Y7zDrPsMaMzRkXzyjs945SxGef8XrbHirrKy1IWO9kelSXNJRd8N9uP8YxSWkvKH2S7nFVNKUWzl_04GbAnGruO9BDOMZDDY3B--YKAM-RkgCEXJNqlg866JVkH3_sBySerg_9yPM85I_h9HTBG690mRq-w9-nCxgGcRmIdWV1BNwbvwJHFm6LIQQ_2EgY0ZIVgNlEO9TmJFyP0fozbfDQEbZ3vYXOMD7P7LXQRH13vB9m3d2-_Lj7kR5_ff1zMj3JdCZmy1QCVaUqoi7YpUQhZU1mBAFqeUs0BdCna0tSnVUsFNVXZGEMNCsNMQVuU4iB7vdVdj6c9Go1uCNCpdbCpQVfKg1V3X5xdqaW_VILVsmE8CTy_Fgj-YsQ4qN7GqQRwmIpTklWsKGQtEnn4X5JR2jSiSHxCn_6BnvkxpKlMemVJKZdNgp5toSV0qKxrfUpQT5pqzuu6qdOvU4Gzv1BpGeytTuZqbbq_E_ByG5BmHmPA9qYZjKrJgyp5UE0eVMmDCX_yewNv4F-mS0C-BWJ6cksMt7X8Q5BseQfDGPB2FE5PzIT8BGLe89E |
CODEN | ONCNES |
CitedBy_id | crossref_primary_10_3390_ijms18091849 crossref_primary_10_1080_00016489_2017_1292049 crossref_primary_10_1007_s10637_016_0397_9 crossref_primary_10_1007_s13277_016_5294_5 crossref_primary_10_3748_wjg_v22_i26_5971 crossref_primary_10_3390_cancers15194898 crossref_primary_10_4161_sgtp_19110 crossref_primary_10_1155_2020_8573793 crossref_primary_10_23902_trkjnat_368829 crossref_primary_10_1038_s41598_017_11709_9 crossref_primary_10_1007_s00106_014_2931_4 crossref_primary_10_3390_cancers12020340 crossref_primary_10_3390_genes15050537 crossref_primary_10_1016_j_gene_2020_144936 crossref_primary_10_1038_onc_2013_173 crossref_primary_10_1053_j_gastro_2013_12_035 crossref_primary_10_1155_2015_186904 crossref_primary_10_1016_j_disamonth_2020_101034 crossref_primary_10_1007_s10620_012_2182_8 crossref_primary_10_1016_j_oraloncology_2020_104916 crossref_primary_10_1155_2016_7614971 crossref_primary_10_1038_srep07461 crossref_primary_10_1186_s12885_018_4631_z crossref_primary_10_3892_or_2015_3710 crossref_primary_10_1038_bjc_2013_349 crossref_primary_10_1038_onc_2013_55 crossref_primary_10_1371_journal_pone_0087444 crossref_primary_10_1371_journal_pone_0093208 crossref_primary_10_3389_fonc_2020_589601 crossref_primary_10_18632_oncotarget_5290 crossref_primary_10_3389_fonc_2023_1247399 crossref_primary_10_3748_wjg_v20_i36_13071 crossref_primary_10_1007_s12035_012_8289_2 crossref_primary_10_1038_cddis_2017_248 crossref_primary_10_1371_journal_pone_0090615 crossref_primary_10_1016_j_oraloncology_2016_10_008 crossref_primary_10_1016_j_bioactmat_2024_05_011 crossref_primary_10_3390_ijms20051151 crossref_primary_10_3892_ijo_2013_1844 crossref_primary_10_1016_j_molonc_2014_05_012 crossref_primary_10_1371_journal_pone_0245871 crossref_primary_10_3389_fcell_2021_660210 crossref_primary_10_1016_j_canlet_2021_03_009 crossref_primary_10_3389_fonc_2019_00492 crossref_primary_10_3389_fonc_2022_909450 crossref_primary_10_1016_j_molmed_2013_10_005 crossref_primary_10_1038_onc_2012_638 crossref_primary_10_1016_j_ygyno_2014_02_033 crossref_primary_10_1007_s11033_019_05058_1 crossref_primary_10_1002_hed_24982 crossref_primary_10_3390_cancers13112759 crossref_primary_10_18632_oncotarget_11349 crossref_primary_10_1586_erm_12_134 crossref_primary_10_1038_srep10205 crossref_primary_10_3390_ijms23031275 crossref_primary_10_3389_fcell_2021_727640 crossref_primary_10_1158_0008_5472_CAN_15_1664 crossref_primary_10_18632_oncotarget_11464 crossref_primary_10_1155_2014_231418 crossref_primary_10_3390_ijms21238936 crossref_primary_10_3892_or_2014_3114 crossref_primary_10_1038_onc_2017_245 crossref_primary_10_1093_jrr_rrad043 crossref_primary_10_1038_s41467_017_01885_7 crossref_primary_10_1016_j_canlet_2012_06_013 crossref_primary_10_1038_s41467_023_35856_y crossref_primary_10_1111_jpi_12940 crossref_primary_10_3390_cells9102200 crossref_primary_10_1016_j_ijcard_2015_05_020 crossref_primary_10_3390_ijms13089545 crossref_primary_10_3892_br_2014_306 crossref_primary_10_1053_j_seminoncol_2015_01_001 crossref_primary_10_1186_s13046_016_0359_2 crossref_primary_10_1095_biolreprod_114_120295 crossref_primary_10_1002_mco2_554 crossref_primary_10_1093_carcin_bgu024 crossref_primary_10_3892_ol_2016_5163 crossref_primary_10_1074_jbc_M111_308528 crossref_primary_10_1158_0008_5472_CAN_20_1079 crossref_primary_10_3233_CBM_201731 crossref_primary_10_3390_cancers11020177 crossref_primary_10_1158_1078_0432_CCR_18_0716 crossref_primary_10_3390_cimb44110360 crossref_primary_10_1002_jcp_30063 crossref_primary_10_1016_j_jconrel_2016_03_008 crossref_primary_10_1097_MD_0000000000002641 crossref_primary_10_4161_cc_23406 crossref_primary_10_1517_14728222_2016_1112791 crossref_primary_10_1016_j_canlet_2018_01_001 crossref_primary_10_1016_j_canlet_2013_02_042 crossref_primary_10_1111_iep_12079 crossref_primary_10_1016_j_oraloncology_2020_105002 crossref_primary_10_1177_1533034615599461 crossref_primary_10_1016_j_ejphar_2021_174147 crossref_primary_10_1002_ijc_28690 crossref_primary_10_1097_CAD_0000000000000783 crossref_primary_10_3390_cancers10120482 crossref_primary_10_1002_hed_25532 crossref_primary_10_1016_j_lfs_2020_118337 crossref_primary_10_1155_2015_989070 crossref_primary_10_1177_1010428317695920 crossref_primary_10_1517_14728222_2013_819853 crossref_primary_10_18632_oncotarget_13422 crossref_primary_10_1111_febs_16179 crossref_primary_10_1158_1078_0432_CCR_12_1436 crossref_primary_10_3892_ol_2013_1690 crossref_primary_10_1158_1078_0432_CCR_13_0595 crossref_primary_10_3389_fbioe_2022_794037 crossref_primary_10_1097_IGC_0000000000000861 crossref_primary_10_1016_j_oraloncology_2015_03_004 crossref_primary_10_3892_ol_2012_907 crossref_primary_10_1016_j_bmc_2024_117603 crossref_primary_10_1155_2020_8868849 crossref_primary_10_1080_01635581_2014_868912 crossref_primary_10_3390_ijms17040517 crossref_primary_10_3389_fgene_2022_864612 crossref_primary_10_3389_fimmu_2015_00235 crossref_primary_10_1002_ijc_31638 crossref_primary_10_1016_j_canlet_2015_11_003 crossref_primary_10_18632_aging_102505 crossref_primary_10_1016_j_ejca_2014_07_012 crossref_primary_10_1038_onc_2015_150 crossref_primary_10_3389_fcell_2018_00097 crossref_primary_10_4161_jkst_28055 crossref_primary_10_1002_jcb_30473 crossref_primary_10_3390_cancers13051021 crossref_primary_10_1016_j_ygyno_2014_01_034 crossref_primary_10_1155_2018_1823726 crossref_primary_10_1016_j_semcancer_2022_10_007 crossref_primary_10_23736_S2724_6329_23_04840_4 crossref_primary_10_3390_ijms20092304 crossref_primary_10_1002_stem_1161 crossref_primary_10_1002_lary_25834 crossref_primary_10_1158_1535_7163_MCT_16_0606 crossref_primary_10_3390_ijms242115812 crossref_primary_10_1016_j_jaut_2012_12_013 crossref_primary_10_1002_1878_0261_13551 crossref_primary_10_1016_j_ijporl_2018_06_043 crossref_primary_10_1096_fj_201900395RR crossref_primary_10_18632_genesandcancer_54 crossref_primary_10_3390_cells8080840 crossref_primary_10_5966_sctm_2015_0048 crossref_primary_10_1097_MOO_0b013e32835e1d6e crossref_primary_10_1158_0008_5472_CAN_14_1254 crossref_primary_10_1186_s12943_018_0833_x crossref_primary_10_3892_br_2016_747 crossref_primary_10_1016_j_acuroe_2019_02_006 crossref_primary_10_1111_jop_12286 crossref_primary_10_1038_onc_2015_281 crossref_primary_10_3389_fonc_2020_01231 crossref_primary_10_1007_s40675_017_0062_7 crossref_primary_10_1111_jop_12449 crossref_primary_10_1016_j_reth_2021_01_004 crossref_primary_10_1002_biof_1813 crossref_primary_10_1007_s13277_016_4848_x crossref_primary_10_1016_j_tibs_2019_06_007 crossref_primary_10_1007_s12015_016_9660_x crossref_primary_10_3390_ijms24054704 crossref_primary_10_3390_pathogens11020266 crossref_primary_10_2217_epi_2021_0228 crossref_primary_10_1007_s00432_013_1494_1 crossref_primary_10_1080_15384047_2015_1121348 crossref_primary_10_1007_s00106_015_0111_9 crossref_primary_10_1007_s12015_018_9839_4 crossref_primary_10_1186_1476_4598_13_52 crossref_primary_10_1080_09513590_2020_1781080 crossref_primary_10_1158_1535_7163_MCT_17_0421 crossref_primary_10_18632_oncotarget_11138 crossref_primary_10_1002_bab_2150 crossref_primary_10_1038_onc_2016_404 crossref_primary_10_3390_ijms22020753 crossref_primary_10_1016_j_critrevonc_2013_07_012 crossref_primary_10_1074_jbc_M115_700021 crossref_primary_10_3390_ijms23158616 crossref_primary_10_1074_jbc_M114_603894 crossref_primary_10_1016_j_acuro_2018_08_003 crossref_primary_10_1016_j_gene_2022_146448 crossref_primary_10_1016_j_bbagen_2014_01_022 crossref_primary_10_1016_j_prp_2023_154949 crossref_primary_10_1093_bib_bbs082 crossref_primary_10_23736_S2724_6329_21_04637_4 crossref_primary_10_1002_stem_2007 |
Cites_doi | 10.1042/bj20030407 10.1158/1078-0432.CCR-07-4404 10.1038/sj.onc.1210856 10.3322/CA.2007.0010 10.1074/jbc.M110.162305 10.1007/s10495-007-0087-3 10.3322/canjclin.55.2.74 10.1002/cncr.21432 10.1073/pnas.0510565103 10.1016/S0092-8674(03)00393-3 10.1074/jbc.R100039200 10.1126/science.277.5332.1630 10.1158/0008-5472.CAN-08-2655 10.1016/0092-8674(95)90311-9 10.1001/archoto.2010.25 10.1016/j.semcancer.2008.03.007 10.1038/nrc2889 10.1002/ijc.23831 10.1074/jbc.M109.027466 10.1158/1078-0432.CCR-06-2313 10.1182/blood-2007-03-081133 10.1016/j.ajpath.2010.11.077 10.1016/S0002-9440(10)64232-0 10.1074/jbc.R100038200 10.1002/lary.20506 10.1038/sj.onc.1203483 10.1074/jbc.M800109200 10.1074/jbc.M806708200 10.1089/scd.2009.0113 |
ContentType | Journal Article |
Copyright | Macmillan Publishers Limited 2012 COPYRIGHT 2012 Nature Publishing Group Copyright Nature Publishing Group Jan 12, 2012 |
Copyright_xml | – notice: Macmillan Publishers Limited 2012 – notice: COPYRIGHT 2012 Nature Publishing Group – notice: Copyright Nature Publishing Group Jan 12, 2012 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TM 7TO 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC P64 PQEST PQQKQ PQUKI Q9U RC3 7T5 7X8 5PM |
DOI | 10.1038/onc.2011.222 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database ProQuest_Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic Genetics Abstracts Immunology Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | Research Library Prep Genetics Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology |
EISSN | 1476-5594 |
EndPage | 160 |
ExternalDocumentID | 2558709601 A277874979 10_1038_onc_2011_222 21685938 onc2011222 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA066163-16 – fundername: NCI NIH HHS grantid: R01 CA066163 – fundername: NIAMS NIH HHS grantid: P01 AR039448-19 – fundername: NIAMS NIH HHS grantid: P01 AR039448 – fundername: NCI NIH HHS grantid: R01 CA78633 – fundername: NCI NIH HHS grantid: R01 CA078633 – fundername: NCI NIH HHS grantid: R01 CA66163 – fundername: NIAMS NIH HHS grantid: P01AR39448 – fundername: NCI NIH HHS grantid: R01 CA078633-10 – fundername: NIAMS NIH HHS grantid: R01 AR050023 |
GroupedDBID | - -Q- 08R 0R 123 29N 2WC 39C 3O- 3V. 4.4 53G 55 5RE 70F 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AADWK AAPBV AAWBL AAYJO AAZLF ABAWZ ABDBF ABDEU ABEFU ABFLS ABGIJ ABPTK ABUWG ACGFS ACKTT ACPRK ADBBV ADBIT ADHDB ADQMX AEDAW AEJRE AENEX AEXYK AFFNX AFKRA AFSHS AGEZK AHMBA AHSBF AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AXYYD AZFZN AZQEC B0M BAWUL BBAFP BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG COF CS3 DIK DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EPL ESX F5P FDQFY FEDTE FERAY FIZPM FRP FSGXE FYUFA GJ GNUQQ GUQSH HCIFZ HVGLF HZ IAO IHR INH INR ITC JSO KQ8 L7B LK8 M0L M1P M2O M7P N9A NAO O9- OK1 OVD P2P PADUT PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q- Q2X RIG RNS RNT RNTTT SNX SNYQT SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS W2D WH7 X7M ZA5 ZXP --- 0R~ 36B 406 AANZL ABAKF ABJNI ABLJU ABZZP ACAOD ACGFO ACMJI ACRQY ACZOJ ADFRT AEMSY AEVLU AFBBN AGHAI AGQEE AILAN ALIPV AMYLF CCPQU DNIVK DPUIP EMOBN HMCUK HZ~ IWAJR JZLTJ NQJWS NXXTH SOHCF SRMVM UKHRP ~8M AAYZH CGR CUY CVF ECM EIF NPM AAYXX CITATION AATNV AAYFA ACBMV ACBRV ACBYP ACIGE ACTTH ACVWB ADMDM ADYYL AEFTE AFNRJ AGGBP AJCLW AJDOV AMRJV FIGPU NYICJ 7TM 7TO 7U9 7XB 8FD 8FK FR3 H94 K9. MBDVC P64 Q9U RC3 7T5 7X8 5PM |
ID | FETCH-LOGICAL-c639t-3caa6d85a74f85e3397096a3a05b0c2aac53f5d7b6f030d658dd0de3d1d40fe93 |
IEDL.DBID | 8C1 |
ISSN | 0950-9232 |
IngestDate | Tue Sep 17 21:01:25 EDT 2024 Fri Oct 25 22:20:54 EDT 2024 Fri Oct 25 09:23:18 EDT 2024 Wed Nov 06 02:53:20 EST 2024 Thu Feb 22 23:38:18 EST 2024 Tue Nov 12 22:52:11 EST 2024 Fri Sep 27 02:37:16 EDT 2024 Tue Oct 15 23:42:10 EDT 2024 Fri Oct 11 20:47:13 EDT 2024 Thu Oct 07 20:38:00 EDT 2021 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | nanog Stat-3 miR-21 hyaluronan CD44 head & neck cancer |
Language | English |
License | Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c639t-3caa6d85a74f85e3397096a3a05b0c2aac53f5d7b6f030d658dd0de3d1d40fe93 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC3179812 |
PMID | 21685938 |
PQID | 915500298 |
PQPubID | 36330 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3179812 proquest_miscellaneous_916144973 proquest_miscellaneous_1008834161 proquest_journals_915500298 gale_infotracmisc_A277874979 gale_infotracacademiconefile_A277874979 crossref_primary_10_1038_onc_2011_222 pubmed_primary_21685938 springer_journals_10_1038_onc_2011_222 nature_primary_onc2011222 |
ProviderPackageCode | ABDEU AEDAW AAZLF -Q- AADWK AAYJO 70F ADQMX EE. RNTTT SWTZT ABGIJ RNT NAO |
PublicationCentury | 2000 |
PublicationDate | 1-12-2012 |
PublicationDateYYYYMMDD | 2012-01-12 |
PublicationDate_xml | – month: 01 year: 2012 text: 1-12-2012 day: 12 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England – name: New York |
PublicationTitle | Oncogene |
PublicationTitleAbbrev | Oncogene |
PublicationTitleAlternate | Oncogene |
PublicationYear | 2012 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Kashyap, V, Rezende, NC, Scotland, KB, Shaffer, SM, Persson, JL, Gudas, LJ 2009; 18 Nakamura, M, Nakatani, K, Uzawa, K, Ono, K, Uesugi, H, Ogawara, K 2005; 14 Bourguignon, LY 2008; 18 Bourguignon, LY, Spevak, CC, Wong, G, Xia, W, Gilad, E 2009a; 284 Wen, Z, Zhong, Z, Darnell, JE 1995; 82 Turley, EA, Noble, PW, Bourguignon, LY 2002; 277 Ezeh, UI, Turek, PJ, Reijo, RA, Clark, AT 2005; 104 Lu, J, Bai, L, Sun, H, Nikolovska-Coleska, Z, McEachern, D, Qiu, S 2008; 68 Volinia, S, Calin, GA, Liu, CG, Ambs, S, Cimmino, A, Petrocca, F 2006; 103 Wang, SJ, Wong, G, de Heer, AM, Xia, W, Bourguignon, LY 2009; 119 Darnell, JE 1997; 277 Gyrd-Hansen, M, Meier, P 2010; 10 Parkin, DM, Bray, F, Ferlay, J, Pisani, P 2005; 55 Huang, S 2007; 13 Löffler, D, Brocke-Heidrich, K, Pfeifer, G, Stocsits, C, Hackermüller, J, Kretzschmar, AK 2007; 110 Bourguignon, LY, Xia, W, Wong, G 2009b; 284 Hunter, AM 2007; 12 Song, JI, Grandis, JR 2000; 19 Toole, BP, Hascall, VC 2002; 161 Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Murray, T 2008; 58 Chang, SS, Jiang, WW, Smith, I, Poeta, LM, Begum, S, Glazer, C 2008; 123 Asangani, IA, Rasheed, SAK, Nikolova, DA, Leupold, JH, Colburn, NH, Post, S 2008; 27 Bourguignon, LY, Peyrollier, K, Xia, W, Gilad, E 2008; 283 Toole, BP, Wight, TN, Tammi, MJ 2002; 277 Bourguignon, LY, Wong, G, Earle, C, Krueger, K, Spevak, CC 2010; 285 Mitsui, K, Tokuzawa, Y, Itoh, H, Segawa, K, Murakami, M, Takahashi, K 2003; 113 Chiou, SH, Yu, CC, Huang, CY, Lin, SC, Liu, CJ, Tsai, TH 2008; 14 Heinrich, PC, Behrmann, I, Haan, S, Hermanns, HM, Muller-Newen, G, Schaper, F 2003; 374 Torre, C, Wang, SJ, Xia, W, Bourguignon, LY 2010; 136 Wang, S, Bourguignon, LY 2011; 178 Darnell (CR9) 1997; 277 Mitsui, Tokuzawa, Itoh, Segawa, Murakami, Takahashi (CR19) 2003; 113 Heinrich, Behrmann, Haan, Hermanns, Muller-Newen, Schaper (CR12) 2003; 374 Huang (CR13) 2007; 13 Bourguignon, Xia, Wong (CR6) 2009; 284 Hunter (CR14) 2007; 12 Wen, Zhong, Darnell (CR30) 1995; 82 Bourguignon, Wong, Earle, Krueger, Spevak (CR5) 2010; 285 Torre, Wang, Xia, Bourguignon (CR25) 2010; 136 Gyrd-Hansen, Meier (CR11) 2010; 10 Chang, Jiang, Smith, Poeta, Begum, Glazer (CR7) 2008; 123 Song, Grandis (CR22) 2000; 19 Ezeh, Turek, Reijo, Clark (CR10) 2005; 104 Bourguignon, Spevak, Wong, Xia, Gilad (CR4) 2009; 284 Wang, Wong, de Heer, Xia, Bourguignon (CR29) 2009; 119 Nakamura, Nakatani, Uzawa, Ono, Uesugi, Ogawara (CR20) 2005; 14 Bourguignon, Peyrollier, Xia, Gilad (CR3) 2008; 283 Chiou, Yu, Huang, Lin, Liu, Tsai (CR8) 2008; 14 Parkin, Bray, Ferlay, Pisani (CR21) 2005; 55 Bourguignon (CR2) 2008; 18 Volinia, Calin, Liu, Ambs, Cimmino, Petrocca (CR27) 2006; 103 Jemal, Siegel, Ward, Hao, Xu, Murray (CR15) 2008; 58 Turley, Noble, Bourguignon (CR26) 2002; 277 Lu, Bai, Sun, Nikolovska-Coleska, McEachern, Qiu (CR18) 2008; 68 Wang, Bourguignon (CR28) 2011; 178 Löffler, Brocke-Heidrich, Pfeifer, Stocsits, Hackermüller, Kretzschmar (CR17) 2007; 110 Toole, Hascall (CR23) 2002; 161 Toole, Wight, Tammi (CR24) 2002; 277 Kashyap, Rezende, Scotland, Shaffer, Persson, Gudas (CR16) 2009; 18 Asangani, Rasheed, Nikolova, Leupold, Colburn, Post (CR1) 2008; 27 20479382 - Arch Otolaryngol Head Neck Surg. 2010 May;136(5):493-501 18441325 - J Biol Chem. 2008 Jun 20;283(25):17635-51 22714418 - Small GTPases. 2012 Jan-Mar;3(1):53-9 21356346 - Am J Pathol. 2011 Mar;178(3):956-63 18593985 - Clin Cancer Res. 2008 Jul 1;14(13):4085-95 19010913 - Cancer Res. 2008 Nov 15;68(22):9384-93 16211297 - Oncol Rep. 2005 Nov;14(5):1281-6 17968323 - Oncogene. 2008 Apr 3;27(15):2128-36 11717318 - J Biol Chem. 2002 Feb 15;277(7):4593-6 18798260 - Int J Cancer. 2008 Dec 15;123(12):2791-7 12787504 - Cell. 2003 May 30;113(5):631-42 12773095 - Biochem J. 2003 Aug 15;374(Pt 1):1-20 17332277 - Clin Cancer Res. 2007 Mar 1;13(5):1362-6 12213700 - Am J Pathol. 2002 Sep;161(3):745-7 18450475 - Semin Cancer Biol. 2008 Aug;18(4):251-9 11717317 - J Biol Chem. 2002 Feb 15;277(7):4589-92 19633292 - J Biol Chem. 2009 Sep 25;284(39):26533-46 19480567 - Stem Cells Dev. 2009 Sep;18(7):1093-108 7543024 - Cell. 1995 Jul 28;82(2):241-50 16228988 - Cancer. 2005 Nov 15;104(10):2255-65 15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 20843787 - J Biol Chem. 2010 Nov 19;285(47):36721-35 19507218 - Laryngoscope. 2009 Aug;119(8):1518-30 17496199 - Blood. 2007 Aug 15;110(4):1330-3 17573556 - Apoptosis. 2007 Sep;12(9):1543-68 16461460 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 19047049 - J Biol Chem. 2009 Jan 30;284(5):2657-71 20651737 - Nat Rev Cancer. 2010 Aug;10(8):561-74 9287210 - Science. 1997 Sep 12;277(5332):1630-5 18287387 - CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 10851047 - Oncogene. 2000 May 15;19(21):2489-95 BP Toole (BFonc2011222_CR23) 2002; 161 Z Wen (BFonc2011222_CR30) 1995; 82 LY Bourguignon (BFonc2011222_CR5) 2010; 285 LY Bourguignon (BFonc2011222_CR4) 2009; 284 S Huang (BFonc2011222_CR13) 2007; 13 A Jemal (BFonc2011222_CR15) 2008; 58 BP Toole (BFonc2011222_CR24) 2002; 277 V Kashyap (BFonc2011222_CR16) 2009; 18 K Mitsui (BFonc2011222_CR19) 2003; 113 JE Darnell Jr (BFonc2011222_CR9) 1997; 277 LY Bourguignon (BFonc2011222_CR3) 2008; 283 S Volinia (BFonc2011222_CR27) 2006; 103 SS Chang (BFonc2011222_CR7) 2008; 123 UI Ezeh (BFonc2011222_CR10) 2005; 104 SJ Wang (BFonc2011222_CR29) 2009; 119 IA Asangani (BFonc2011222_CR1) 2008; 27 LY Bourguignon (BFonc2011222_CR6) 2009; 284 EA Turley (BFonc2011222_CR26) 2002; 277 S Wang (BFonc2011222_CR28) 2011; 178 M Nakamura (BFonc2011222_CR20) 2005; 14 D Löffler (BFonc2011222_CR17) 2007; 110 DM Parkin (BFonc2011222_CR21) 2005; 55 LY Bourguignon (BFonc2011222_CR2) 2008; 18 SH Chiou (BFonc2011222_CR8) 2008; 14 JI Song (BFonc2011222_CR22) 2000; 19 PC Heinrich (BFonc2011222_CR12) 2003; 374 AM Hunter (BFonc2011222_CR14) 2007; 12 J Lu (BFonc2011222_CR18) 2008; 68 M Gyrd-Hansen (BFonc2011222_CR11) 2010; 10 C Torre (BFonc2011222_CR25) 2010; 136 |
References_xml | – volume: 13 start-page: 1362 year: 2007 end-page: 1366 article-title: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications publication-title: Clin Cancer Res contributor: fullname: Huang, S – volume: 123 start-page: 2791 year: 2008 end-page: 2797 article-title: MicroRNA alterations in head and neck squamous cell carcinoma publication-title: Int J Cancer contributor: fullname: Glazer, C – volume: 103 start-page: 2257 year: 2006 end-page: 2261 article-title: A microRNA expression signature of human solid tumors defines cancer gene targets publication-title: Proc Natl Acad Sci USA contributor: fullname: Petrocca, F – volume: 55 start-page: 74 year: 2005 end-page: 108 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin contributor: fullname: Pisani, P – volume: 19 start-page: 2489 year: 2000 end-page: 2495 article-title: STAT signaling in head and neck cancer publication-title: Oncogene contributor: fullname: Grandis, JR – volume: 285 start-page: 36721 year: 2010 end-page: 36735 article-title: Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression and RhoA RhoC upregulation leading to Rho-Kinase-associated cytoskeleton activation and breast tumor cell invasion publication-title: J Biol Chem contributor: fullname: Spevak, CC – volume: 10 start-page: 561 year: 2010 end-page: 574 article-title: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer publication-title: Nat Rev Cancer contributor: fullname: Meier, P – volume: 14 start-page: 1281 year: 2005 end-page: 1286 article-title: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R publication-title: Oncol Rep contributor: fullname: Ogawara, K – volume: 12 start-page: 1543 year: 2007 end-page: 1568 article-title: The inhibitors of apoptosis (IAPs) as cancer targets publication-title: Apoptosis contributor: fullname: Hunter, AM – volume: 161 start-page: 745 year: 2002 end-page: 747 article-title: Hyaluronan and tumor growth publication-title: Am J Pathol contributor: fullname: Hascall, VC – volume: 14 start-page: 4085 year: 2008 end-page: 4095 article-title: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma publication-title: Clin Cancer Res contributor: fullname: Tsai, TH – volume: 283 start-page: 17635 year: 2008 end-page: 17651 article-title: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells publication-title: J Biol Chem contributor: fullname: Gilad, E – volume: 284 start-page: 2657 year: 2009b end-page: 2671 article-title: Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells publication-title: J Biol Chem contributor: fullname: Wong, G – volume: 374 start-page: 1 year: 2003 end-page: 20 article-title: Principles of interleukin (IL)-6-type cytokine signalling and its regulation publication-title: Biochem J contributor: fullname: Schaper, F – volume: 284 start-page: 26533 year: 2009a end-page: 26546 article-title: Hyaluronan-CD44 interaction with PKC promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells publication-title: J Biol Chem contributor: fullname: Gilad, E – volume: 104 start-page: 2255 year: 2005 end-page: 2265 article-title: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma publication-title: Cancer contributor: fullname: Clark, AT – volume: 136 start-page: 493 year: 2010 end-page: 501 article-title: Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling publication-title: Arch Otolaryngol Head Neck Surg contributor: fullname: Bourguignon, LY – volume: 178 start-page: 956 year: 2011 end-page: 963 article-title: Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance publication-title: Am J Pathol contributor: fullname: Bourguignon, LY – volume: 27 start-page: 2128 year: 2008 end-page: 2136 article-title: Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer publication-title: Oncogene contributor: fullname: Post, S – volume: 58 start-page: 71 year: 2008 end-page: 96 article-title: Cancer statistics, 2008 publication-title: CA Cancer J Clin contributor: fullname: Murray, T – volume: 18 start-page: 1093 year: 2009 end-page: 1108 article-title: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs publication-title: Stem Cells Dev contributor: fullname: Gudas, LJ – volume: 110 start-page: 1330 year: 2007 end-page: 1333 article-title: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer publication-title: Blood contributor: fullname: Kretzschmar, AK – volume: 82 start-page: 241 year: 1995 end-page: 250 article-title: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation publication-title: Cell contributor: fullname: Darnell, JE – volume: 119 start-page: 1518 year: 2009 end-page: 1530 article-title: CD44 variant isoforms in head and neck squamous cell carcinoma progression publication-title: Laryngoscope contributor: fullname: Bourguignon, LY – volume: 68 start-page: 9384 year: 2008 end-page: 9393 article-title: SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1 2 and XIAP publication-title: Cancer Res contributor: fullname: Qiu, S – volume: 113 start-page: 631 year: 2003 end-page: 642 article-title: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells publication-title: Cell contributor: fullname: Takahashi, K – volume: 18 start-page: 251 year: 2008 end-page: 259 article-title: Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression publication-title: Semin Cancer Biol contributor: fullname: Bourguignon, LY – volume: 277 start-page: 1630 year: 1997 end-page: 1635 article-title: STATs and gene regulation publication-title: Science contributor: fullname: Darnell, JE – volume: 277 start-page: 4593 year: 2002 end-page: 4596 article-title: Hyaluronan-cell interactions in cancer and vascular disease publication-title: J Biol Chem contributor: fullname: Tammi, MJ – volume: 277 start-page: 4589 year: 2002 end-page: 4592 article-title: Signaling properties of hyaluronan receptors publication-title: J Biol Chem contributor: fullname: Bourguignon, LY – volume: 374 start-page: 1 year: 2003 end-page: 20 ident: CR12 article-title: Principles of interleukin (IL)-6-type cytokine signalling and its regulation publication-title: Biochem J doi: 10.1042/bj20030407 contributor: fullname: Schaper – volume: 14 start-page: 4085 year: 2008 end-page: 4095 ident: CR8 article-title: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4404 contributor: fullname: Tsai – volume: 27 start-page: 2128 year: 2008 end-page: 2136 ident: CR1 article-title: Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer publication-title: Oncogene doi: 10.1038/sj.onc.1210856 contributor: fullname: Post – volume: 58 start-page: 71 year: 2008 end-page: 96 ident: CR15 article-title: Cancer statistics, 2008 publication-title: CA Cancer J Clin doi: 10.3322/CA.2007.0010 contributor: fullname: Murray – volume: 14 start-page: 1281 year: 2005 end-page: 1286 ident: CR20 article-title: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R publication-title: Oncol Rep contributor: fullname: Ogawara – volume: 285 start-page: 36721 year: 2010 end-page: 36735 ident: CR5 article-title: Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression and RhoA/RhoC upregulation leading to Rho-Kinase-associated cytoskeleton activation and breast tumor cell invasion publication-title: J Biol Chem doi: 10.1074/jbc.M110.162305 contributor: fullname: Spevak – volume: 12 start-page: 1543 year: 2007 end-page: 1568 ident: CR14 article-title: The inhibitors of apoptosis (IAPs) as cancer targets publication-title: Apoptosis doi: 10.1007/s10495-007-0087-3 contributor: fullname: Hunter – volume: 55 start-page: 74 year: 2005 end-page: 108 ident: CR21 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 contributor: fullname: Pisani – volume: 104 start-page: 2255 year: 2005 end-page: 2265 ident: CR10 article-title: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma publication-title: Cancer doi: 10.1002/cncr.21432 contributor: fullname: Clark – volume: 103 start-page: 2257 year: 2006 end-page: 2261 ident: CR27 article-title: A microRNA expression signature of human solid tumors defines cancer gene targets publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0510565103 contributor: fullname: Petrocca – volume: 113 start-page: 631 year: 2003 end-page: 642 ident: CR19 article-title: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells publication-title: Cell doi: 10.1016/S0092-8674(03)00393-3 contributor: fullname: Takahashi – volume: 277 start-page: 4593 year: 2002 end-page: 4596 ident: CR24 article-title: Hyaluronan-cell interactions in cancer and vascular disease publication-title: J Biol Chem doi: 10.1074/jbc.R100039200 contributor: fullname: Tammi – volume: 277 start-page: 1630 year: 1997 end-page: 1635 ident: CR9 article-title: STATs and gene regulation publication-title: Science doi: 10.1126/science.277.5332.1630 contributor: fullname: Darnell – volume: 68 start-page: 9384 year: 2008 end-page: 9393 ident: CR18 article-title: SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2655 contributor: fullname: Qiu – volume: 82 start-page: 241 year: 1995 end-page: 250 ident: CR30 article-title: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation publication-title: Cell doi: 10.1016/0092-8674(95)90311-9 contributor: fullname: Darnell – volume: 136 start-page: 493 year: 2010 end-page: 501 ident: CR25 article-title: Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling publication-title: Arch Otolaryngol Head Neck Surg doi: 10.1001/archoto.2010.25 contributor: fullname: Bourguignon – volume: 18 start-page: 251 year: 2008 end-page: 259 ident: CR2 article-title: Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.03.007 contributor: fullname: Bourguignon – volume: 10 start-page: 561 year: 2010 end-page: 574 ident: CR11 article-title: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc2889 contributor: fullname: Meier – volume: 123 start-page: 2791 year: 2008 end-page: 2797 ident: CR7 article-title: MicroRNA alterations in head and neck squamous cell carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.23831 contributor: fullname: Glazer – volume: 284 start-page: 26533 year: 2009 end-page: 26546 ident: CR4 article-title: Hyaluronan-CD44 interaction with PKCɛ promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells publication-title: J Biol Chem doi: 10.1074/jbc.M109.027466 contributor: fullname: Gilad – volume: 13 start-page: 1362 year: 2007 end-page: 1366 ident: CR13 article-title: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2313 contributor: fullname: Huang – volume: 110 start-page: 1330 year: 2007 end-page: 1333 ident: CR17 article-title: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer publication-title: Blood doi: 10.1182/blood-2007-03-081133 contributor: fullname: Kretzschmar – volume: 178 start-page: 956 year: 2011 end-page: 963 ident: CR28 article-title: Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance publication-title: Am J Pathol doi: 10.1016/j.ajpath.2010.11.077 contributor: fullname: Bourguignon – volume: 161 start-page: 745 year: 2002 end-page: 747 ident: CR23 article-title: Hyaluronan and tumor growth publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)64232-0 contributor: fullname: Hascall – volume: 277 start-page: 4589 year: 2002 end-page: 4592 ident: CR26 article-title: Signaling properties of hyaluronan receptors publication-title: J Biol Chem doi: 10.1074/jbc.R100038200 contributor: fullname: Bourguignon – volume: 119 start-page: 1518 year: 2009 end-page: 1530 ident: CR29 article-title: CD44 variant isoforms in head and neck squamous cell carcinoma progression publication-title: Laryngoscope doi: 10.1002/lary.20506 contributor: fullname: Bourguignon – volume: 19 start-page: 2489 year: 2000 end-page: 2495 ident: CR22 article-title: STAT signaling in head and neck cancer publication-title: Oncogene doi: 10.1038/sj.onc.1203483 contributor: fullname: Grandis – volume: 283 start-page: 17635 year: 2008 end-page: 17651 ident: CR3 article-title: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells publication-title: J Biol Chem doi: 10.1074/jbc.M800109200 contributor: fullname: Gilad – volume: 284 start-page: 2657 year: 2009 end-page: 2671 ident: CR6 article-title: Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells publication-title: J Biol Chem doi: 10.1074/jbc.M806708200 contributor: fullname: Wong – volume: 18 start-page: 1093 year: 2009 end-page: 1108 ident: CR16 article-title: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs publication-title: Stem Cells Dev doi: 10.1089/scd.2009.0113 contributor: fullname: Gudas – volume: 103 start-page: 2257 year: 2006 ident: BFonc2011222_CR27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0510565103 contributor: fullname: S Volinia – volume: 27 start-page: 2128 year: 2008 ident: BFonc2011222_CR1 publication-title: Oncogene doi: 10.1038/sj.onc.1210856 contributor: fullname: IA Asangani – volume: 284 start-page: 26533 year: 2009 ident: BFonc2011222_CR4 publication-title: J Biol Chem doi: 10.1074/jbc.M109.027466 contributor: fullname: LY Bourguignon – volume: 82 start-page: 241 year: 1995 ident: BFonc2011222_CR30 publication-title: Cell doi: 10.1016/0092-8674(95)90311-9 contributor: fullname: Z Wen – volume: 10 start-page: 561 year: 2010 ident: BFonc2011222_CR11 publication-title: Nat Rev Cancer doi: 10.1038/nrc2889 contributor: fullname: M Gyrd-Hansen – volume: 55 start-page: 74 year: 2005 ident: BFonc2011222_CR21 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 contributor: fullname: DM Parkin – volume: 136 start-page: 493 year: 2010 ident: BFonc2011222_CR25 publication-title: Arch Otolaryngol Head Neck Surg doi: 10.1001/archoto.2010.25 contributor: fullname: C Torre – volume: 178 start-page: 956 year: 2011 ident: BFonc2011222_CR28 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2010.11.077 contributor: fullname: S Wang – volume: 119 start-page: 1518 year: 2009 ident: BFonc2011222_CR29 publication-title: Laryngoscope doi: 10.1002/lary.20506 contributor: fullname: SJ Wang – volume: 18 start-page: 251 year: 2008 ident: BFonc2011222_CR2 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2008.03.007 contributor: fullname: LY Bourguignon – volume: 18 start-page: 1093 year: 2009 ident: BFonc2011222_CR16 publication-title: Stem Cells Dev doi: 10.1089/scd.2009.0113 contributor: fullname: V Kashyap – volume: 277 start-page: 4593 year: 2002 ident: BFonc2011222_CR24 publication-title: J Biol Chem doi: 10.1074/jbc.R100039200 contributor: fullname: BP Toole – volume: 285 start-page: 36721 year: 2010 ident: BFonc2011222_CR5 publication-title: J Biol Chem doi: 10.1074/jbc.M110.162305 contributor: fullname: LY Bourguignon – volume: 58 start-page: 71 year: 2008 ident: BFonc2011222_CR15 publication-title: CA Cancer J Clin doi: 10.3322/CA.2007.0010 contributor: fullname: A Jemal – volume: 14 start-page: 1281 year: 2005 ident: BFonc2011222_CR20 publication-title: Oncol Rep contributor: fullname: M Nakamura – volume: 104 start-page: 2255 year: 2005 ident: BFonc2011222_CR10 publication-title: Cancer doi: 10.1002/cncr.21432 contributor: fullname: UI Ezeh – volume: 13 start-page: 1362 year: 2007 ident: BFonc2011222_CR13 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2313 contributor: fullname: S Huang – volume: 113 start-page: 631 year: 2003 ident: BFonc2011222_CR19 publication-title: Cell doi: 10.1016/S0092-8674(03)00393-3 contributor: fullname: K Mitsui – volume: 161 start-page: 745 year: 2002 ident: BFonc2011222_CR23 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)64232-0 contributor: fullname: BP Toole – volume: 110 start-page: 1330 year: 2007 ident: BFonc2011222_CR17 publication-title: Blood doi: 10.1182/blood-2007-03-081133 contributor: fullname: D Löffler – volume: 14 start-page: 4085 year: 2008 ident: BFonc2011222_CR8 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4404 contributor: fullname: SH Chiou – volume: 123 start-page: 2791 year: 2008 ident: BFonc2011222_CR7 publication-title: Int J Cancer doi: 10.1002/ijc.23831 contributor: fullname: SS Chang – volume: 68 start-page: 9384 year: 2008 ident: BFonc2011222_CR18 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2655 contributor: fullname: J Lu – volume: 284 start-page: 2657 year: 2009 ident: BFonc2011222_CR6 publication-title: J Biol Chem doi: 10.1074/jbc.M806708200 contributor: fullname: LY Bourguignon – volume: 277 start-page: 1630 year: 1997 ident: BFonc2011222_CR9 publication-title: Science doi: 10.1126/science.277.5332.1630 contributor: fullname: JE Darnell Jr – volume: 12 start-page: 1543 year: 2007 ident: BFonc2011222_CR14 publication-title: Apoptosis doi: 10.1007/s10495-007-0087-3 contributor: fullname: AM Hunter – volume: 374 start-page: 1 year: 2003 ident: BFonc2011222_CR12 publication-title: Biochem J doi: 10.1042/bj20030407 contributor: fullname: PC Heinrich – volume: 19 start-page: 2489 year: 2000 ident: BFonc2011222_CR22 publication-title: Oncogene doi: 10.1038/sj.onc.1203483 contributor: fullname: JI Song – volume: 283 start-page: 17635 year: 2008 ident: BFonc2011222_CR3 publication-title: J Biol Chem doi: 10.1074/jbc.M800109200 contributor: fullname: LY Bourguignon – volume: 277 start-page: 4589 year: 2002 ident: BFonc2011222_CR26 publication-title: J Biol Chem doi: 10.1074/jbc.R100038200 contributor: fullname: EA Turley |
SSID | ssj0007902 |
Score | 2.5254774 |
Snippet | MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21... MicroRNAs are often associated with the pathogenesis of many cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). In particular, microRNA-21... |
SourceID | pubmedcentral proquest gale crossref pubmed springer nature |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 149 |
SubjectTerms | Apoptosis Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - pathology CD44 antigen Cell Biology Cell Line, Tumor Cell Nucleus - metabolism Cell survival Chemoresistance Chemotherapy Chromatin Drug resistance Drug Resistance, Neoplasm Gene expression Genetic aspects Head & neck cancer Head and neck cancer Head and Neck Neoplasms - genetics Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - pathology Homeodomain Proteins - metabolism Human Genetics Humans hyaluronan Hyaluronan Receptors - metabolism Hyaluronic Acid - metabolism IAP protein Immunoprecipitation Internal Medicine Medicine Medicine & Public Health MicroRNA MicroRNAs - genetics MicroRNAs - metabolism miRNA Nanog Homeobox Protein Nuclear transport Oncology original-article Physiological aspects Promoter Regions, Genetic Promoters Signal Transduction siRNA squamous cell carcinoma Stat3 protein STAT3 Transcription Factor - metabolism Stem cells Transcription activation Tumor cells Tumor suppressor genes Tumors Tyrosine |
Title | Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan CD44-activated head and neck squamous cell carcinoma cells |
URI | http://dx.doi.org/10.1038/onc.2011.222 https://link.springer.com/article/10.1038/onc.2011.222 https://www.ncbi.nlm.nih.gov/pubmed/21685938 https://www.proquest.com/docview/915500298 https://search.proquest.com/docview/1008834161 https://search.proquest.com/docview/916144973 https://pubmed.ncbi.nlm.nih.gov/PMC3179812 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zb9swDBbWFjtehi27vHaBBux8EGJbki0_DVnWohiQYOhWoG-GIslrsEVJcwDrT9q_HCk7CbzrMZBsMiZNfpI-k4S8GBcKgLJUTEplmdCpYFoIzmLjClOZmKvQpnM4yk7PxccLedFwc5YNrXITE0OgtjODe-Q9rGMe6oW_m18xbBqFh6tNB409cpBAmkNGnxrsGB55TTkEEBEzwDFpw3sH-b2ZN3X5zjRNWxmpicvtspot2Pkne_K3I9SQmU7ukbsNpKT92gfukxvOd8jNusnkdYfcHmx6unXIrWFzlP6A_Py8clOK-_Z0ihSdBX0DkXb29S3V3lLEoIxTZHdo_GCdzgNtz9EhEvjORn2WJtT9aFi0PlwD5kfW7hIRKbgSnXh6ea2_rxcA9n1v8EGAgUzopuYshRxgw1XemW90ebXWuAdR62Owv5GfTXX4uXxIzk-OvwxOWdO3gRnAO6Cd0TqzSupcVEo6DpAHFkqa61iOY5NqbSSvpM3HWQUhxoKnWBtbx21iRVy5gj8i-37m3RNC4T4chjNIsFK4LFOJEdYU0hkscjOuIvJyY7tyXpfnKMOxOlcl2LhEG5dg44i8RsOW-NaC0YxuPj4AKVj_quynOUQuUeRFRI5aM8FApjUc1a6xFQdiUEoQcrjxlrKJBMty67cReb4dxZsiuc07eLRYNlopjivNiNB_zAEUD0vfIucReVy731aBNMmwaB0IyFuOudNQT8r2iJ9chkriHMvVJaD4q40L7xT_22N8-t9_eEjuwERk-rAkPSL7q8XaPQPIthp3yV5-kXfD69klB--PR5_OfgFMMEIx |
link.rule.ids | 230,315,783,787,888,12068,12235,21400,27936,27937,31731,31732,33278,33279,33756,33757,43322,43591,43817,74073,74342,74630 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgESwXBOUVdgEj8TxYTWI7jxOqCqsC2x5gV-rNcm2HraButw-J_Un8S2actKvwOlaOM25mMv5sf_mGkOeTsgCgLAsmZWGZ0KlgWgjOYuNKU5mYF6FM53CUDU7Fx7EcN9ycVUOr3ObEkKjt3OAeeRd1zINe-NvFOcOiUXi42lTQuEquoQwXFjDIx7v1VpzXlEMAETEDHJM2vHew3517U8t3pmnampGavNyW1WzBzj_Zk78doYaZ6eg2udVAStqrY-AOueJ8h1yvi0xedMh-f1vTrUNuDJuj9Lvk55e1m1Hct6czpOgs6WvItPOvb6j2liIGZZwiu0PjB-t0EWh7jg6RwPd51GNpQt2PhkXrQx9wP7J2V4hIIZTo1NOzC_19swSw77v9dwIcZEI1NWcpzAE29PLOfKOr843GPYh6PAbrG_n5TIefq3vk9Oj9SX_AmroNzADegdEZrTNbSJ2LqpCOA-SBhZLmOpaT2KRaG8krafNJVkGKsRAp1sbWcZtYEVeu5PfJnp9795BQuA-H5gwmWClclhWJEdaU0hkUuZlUEXmx9Z1a1PIcKhyr80KBjxX6WIGPI_IKHavwrQWnGd18fABWUP9K9dIcMpco8zIih60rwUGm1RzVobEzB2bQSjBysI0W1WSCldrFbUSe7Vrxpkhu8w4eLcpGFwXHlWZE6D-uARQPS98y5xF5UIffbgBpkqFoHRjIW4F5OUI9Ve0WPz0LSuIc5eoSGPjLbQhfDvxvj_HRf__hU7I_OBkeq-MPo08H5CZ0QtYPS9JDsrdebtxjgG_ryZPwkv4CQ6ZCzw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zj9MwELZgEQsvCMoVdgEjcT5YTeI4xxOqulTL0QoBK_XNcm2HraBut4fE_iT-JTOO21W4HivH8TQzGX-2v3xDyNNJVQJQFiUTojQsU2nGVJZxFmtb6VrHvPRlOoej_PgkezcW4yAptAq0ym1O9InazDXukXdRx9zrhXfrwIr4eDR4vThjWEAKD1pDNY3L5EoBixQM-WK8W3vFRUM_BEARM8A0aeDAgy3dudONlGeapq3ZKeTotsRmC4L-yaT87TjVz1KDm-RGgJe018TDLXLJug652hScPO-Qa_1tfbcO2R-GY_Xb5OfntZ1R3MOnM6TrLOlLyLrzr6-ocoYiHmWcItND4cfrdOEpfJYOkcz3adRjaULtj8Codb4PhAIyeFeITiGs6NTR03P1fbME4O-6_aMMnKV9ZTVrKMwHxvdyVn-jq7ONwv2Ixh6NtY7cfKb8z9UdcjJ486V_zEINB6YB-4B1WqnclEIVWV0KywH-wKJJcRWLSaxTpbTgtTDFJK8h3RiIGmNiY7lJTBbXtuJ3yZ6bO3ufULgPh-YcJluR2TwvE50ZXQmrUfBmUkfk2dZ3ctFIdUh_xM5LCT6W6GMJPo7IC3SsxDcYnKZV-BABRkEtLNlLC8hiWVVUETlsXQkO0q3mqAmN3XAwDI7iBznYRosMWWEldzEckSe7VrwpEt2chUeLEtJlyXHVGRH6j2sA0cMyuCp4RO414bczIE1yFLCDAYpWYF5YqKay3eKmp15VnKN0XQKGP9-G8IXhf3uMD_77Dx-TfXg_5Ye3o_cH5Dr0QQIQS9JDsrdebuxDQHLrySP_jv4CnXlHBw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stem+cell+marker+%28Nanog%29+and+Stat-3+signaling+promote+MicroRNA-21+expression+and+chemoresistance+in+hyaluronan%2FCD44-activated+head+and+neck+squamous+cell+carcinoma+cells&rft.jtitle=Oncogene&rft.au=Bourguignon%2C+L+Y+W&rft.au=Earle%2C+C&rft.au=Wong%2C+G&rft.au=Spevak%2C+C+C&rft.date=2012-01-12&rft.issn=0950-9232&rft.volume=31&rft.issue=2&rft.spage=149&rft.epage=160&rft_id=info:doi/10.1038%2Fonc.2011.222&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |